Mangoceuticals (NASDAQ:MGRX) Issues Quarterly Earnings Results

Mangoceuticals (NASDAQ:MGRX) announced its earnings results on Wednesday. The company reported $0.13 EPS for the quarter, Zacks reports. The business had revenue of $0.09 million during the quarter. Mangoceuticals had a negative net margin of 4,253.43% and a negative return on equity of 114.63%.

Mangoceuticals Stock Down 4.4%

Shares of MGRX traded down $0.02 during mid-day trading on Thursday, hitting $0.34. 376,918 shares of the company traded hands, compared to its average volume of 12,301,212. The company has a market capitalization of $5.60 million, a PE ratio of -0.10 and a beta of 2.54. The business has a 50 day moving average of $0.40 and a 200 day moving average of $1.15. Mangoceuticals has a 1-year low of $0.16 and a 1-year high of $2.88.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mangoceuticals in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new position in Mangoceuticals during the 4th quarter valued at approximately $25,000. Boothbay Fund Management LLC acquired a new stake in shares of Mangoceuticals during the fourth quarter worth $28,000. Jane Street Group LLC purchased a new stake in shares of Mangoceuticals during the fourth quarter valued at $35,000. Geode Capital Management LLC increased its position in shares of Mangoceuticals by 35.4% in the 2nd quarter. Geode Capital Management LLC now owns 26,498 shares of the company’s stock valued at $40,000 after acquiring an additional 6,928 shares during the period. Finally, Ikarian Capital LLC acquired a new position in shares of Mangoceuticals in the 4th quarter valued at $102,000. Institutional investors and hedge funds own 56.72% of the company’s stock.

About Mangoceuticals

Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.